CareDx, Inc. (NASDAQ:CDNA) COO Mitchell J. Nelles sold 10,948 shares of CareDx stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $7.17, for a total transaction of $78,497.16. Following the sale, the chief operating officer now directly owns 84,225 shares in the company, valued at approximately $603,893.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shares of CareDx, Inc. (NASDAQ CDNA) traded up $0.12 during mid-day trading on Thursday, hitting $7.26. 143,649 shares of the stock traded hands, compared to its average volume of 356,003. The company has a debt-to-equity ratio of -124.53, a quick ratio of 0.35 and a current ratio of 0.55. CareDx, Inc. has a 1 year low of $0.76 and a 1 year high of $7.98.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.02. The firm had revenue of $12.19 million for the quarter, compared to analysts’ expectations of $12.05 million. CareDx had a negative net margin of 84.14% and a negative return on equity of 157.00%. The company’s revenue was down 2.3% on a year-over-year basis. analysts forecast that CareDx, Inc. will post -0.83 earnings per share for the current year.

Several equities research analysts have issued reports on the stock. ValuEngine raised shares of CareDx from a “strong sell” rating to a “sell” rating in a research note on Tuesday, September 26th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $7.00 target price (up previously from $3.00) on shares of CareDx in a research note on Tuesday, September 26th. HC Wainwright assumed coverage on shares of CareDx in a research note on Monday. They set a “buy” rating and a $12.00 target price on the stock. Craig Hallum reaffirmed a “buy” rating and set a $10.00 target price (up previously from $4.00) on shares of CareDx in a research note on Monday, October 9th. Finally, Raymond James Financial raised shares of CareDx from a “market perform” rating to a “buy” rating and set a $6.50 target price on the stock in a research note on Wednesday, September 27th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $7.75.

Several hedge funds have recently made changes to their positions in the company. Gagnon Securities LLC boosted its position in shares of CareDx by 3.9% during the 3rd quarter. Gagnon Securities LLC now owns 2,166,403 shares of the company’s stock valued at $8,016,000 after acquiring an additional 82,111 shares during the last quarter. Royce & Associates LP boosted its position in shares of CareDx by 8.1% during the 3rd quarter. Royce & Associates LP now owns 792,787 shares of the company’s stock valued at $2,933,000 after acquiring an additional 59,500 shares during the last quarter. Private Wealth Partners LLC boosted its position in shares of CareDx by 2,250.0% during the 3rd quarter. Private Wealth Partners LLC now owns 235,000 shares of the company’s stock valued at $869,000 after acquiring an additional 225,000 shares during the last quarter. Thompson Davis & CO. Inc. boosted its position in shares of CareDx by 3,294.9% during the 3rd quarter. Thompson Davis & CO. Inc. now owns 203,692 shares of the company’s stock valued at $754,000 after acquiring an additional 197,692 shares during the last quarter. Finally, Stonepine Capital Management LLC acquired a new position in shares of CareDx during the 2nd quarter valued at about $212,000. 23.15% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/11/30/caredx-inc-cdna-coo-mitchell-j-nelles-sells-10948-shares.html.

CareDx Company Profile

CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.

Insider Buying and Selling by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.